Literature DB >> 11467056

Neuropathology of amyotrophic lateral sclerosis with extra-motor system degeneration: characteristics and differences in the molecular pathology between ALS with dementia and Guamanian ALS.

A Ikemoto1, A Hirano, I Akiguchi.   

Abstract

Amyotrophic lateral sclerosis (ALS) is classified into distinct subtypes mainly based on clinicopathological features, in addition to epidemiologic and genetic backgrounds. In addition to sporadic ALS with classical pathology, characteristics in the clinical features, in the histological findings and their topographical distribution, and in the molecular pathology, especially the intracytoplasmic neuronal inclusions, enable us to identify the following subtypes: ALS with dementia (ALS-D), ALS in the Western Pacific, ALS with multi-system degeneration, familial ALS, and superoxide dismutase 1-linked ALS. These subtypes not infrequently exhibit various types of extra-motor system degeneration, and even multi-system pathology. Some of the subtypes (for instance ALS-D or familial ALS) can be deduced, to a certain extent, from characteristic neuronal inclusions such as ALS-type ubiquitinated inclusions, Lewy body-like hyaline inclusions (LBHIs), or ubiquitinated intracytoplasmic neuronal inclusions as typically seen in the dentate fascia. The purpose of this article is to clarify the molecular pathogenesis of the cerebral cortex in ALS-D and Guamanian ALS and parkinsonism-dementia complex (PDC), in order to elucidate the relationship and distinction between these two subtypes. As indicated previously, investigations on ubiquitin-immunoreactivity in the hippocampus further support the view that the pathology of G-ALS/PDC may be that of a tau-related tangle disorder, whilst ALS-D has a feature of the motor neuron disease type-frontotemporal dementia.

Entities:  

Mesh:

Year:  2000        PMID: 11467056     DOI: 10.1080/14660820050515395

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  6 in total

1.  Interaction of amyotrophic lateral sclerosis (ALS)-related mutant copper-zinc superoxide dismutase with the dynein-dynactin complex contributes to inclusion formation.

Authors:  Anna-Lena Ström; Ping Shi; Fujian Zhang; Jozsef Gal; Renee Kilty; Lawrence J Hayward; Haining Zhu
Journal:  J Biol Chem       Date:  2008-05-30       Impact factor: 5.157

Review 2.  A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.

Authors:  N Chernoff; D J Hill; D L Diggs; B D Faison; B M Francis; J R Lang; M M Larue; T-T Le; K A Loftin; J N Lugo; J E Schmid; W M Winnik
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017-06-09       Impact factor: 6.393

3.  Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease.

Authors:  N J Cairns; M Grossman; S E Arnold; D J Burn; E Jaros; R H Perry; C Duyckaerts; B Stankoff; B Pillon; K Skullerud; F F Cruz-Sanchez; E H Bigio; I R A Mackenzie; M Gearing; J L Juncos; J D Glass; H Yokoo; Y Nakazato; S Mosaheb; J R Thorpe; K Uryu; V M-Y Lee; J Q Trojanowski
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

4.  Degeneration of the mid-cingulate cortex in amyotrophic lateral sclerosis detected in vivo with MR spectroscopy.

Authors:  N Sudharshan; C Hanstock; B Hui; T Pyra; W Johnston; S Kalra
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-18       Impact factor: 3.825

5.  Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.

Authors:  Sheila K Pirooznia; Felice Elefant
Journal:  Front Cell Neurosci       Date:  2013-03-28       Impact factor: 5.505

6.  Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Fang Cui; Wenjia Zhu; Zhibin Zhou; Yuting Ren; Yifan Li; Mao Li; Yunyun Huo; Xusheng Huang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-03       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.